This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
New insights into clinical trial for Colostrinin in Alzheimer’s disease
Szaniszlo, P.,
German, P.,
Hajas, G.,
Saenz, D. N.,
Kruzel, M.,
Boldogh, I.
Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular […]
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia
Sommer, Oskar H.,
Aga, Olav,
Cvancarova, Milada,
Olsen, Inge C.,
Selbaek, Geir,
Engedal, Knut
Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]
Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
Schmidt, Reinhold,
Alf, Claude,
Bancher, Christian,
Benke, Thomas,
Berek, Klaus,
Dal-Bianco, Peter,
Führwürth, Gerhard,
Imarhiagbe, Douglas,
Jagsch, Christian,
Lechner, Anita,
Rainer, Michael,
Reisecker, Franz,
Rotaru, Juliana,
Uranüs, Margarete,
Walter, Andreas,
Winkler, Andreas,
Wuschitz, Albert
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
Vascular care in patients with Alzheimer’s disease with cerebrovascular lesions-a randomized clinical trial
Objectives: To investigate whether vascular care slows dementia progression in patients with Alzheimer’s disease with cerebrovascular lesions on neuroimaging.; Design: Multicenter randomized controlled clinical trial with 2-year follow-up.; Setting: Neurological and geriatric outpatient clinics in 10 Dutch hospitals: three academic, five teaching, and two midsize community hospitals.; Participants: One hundred thirty community-dwelling patients with mild […]